Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)

• Název česky: Ingavirin může být slibnou sloučeninou v boji proti koronaviru 2 vyvolávajícímu těžký akutní respirační syndrom (SARS-CoV-2)
• Autoři: MALÍK Ivan; KOVÁČ Gustav; KOVÁČ Gustav; PADRTOVÁ Tereza; PADRTOVÁ Tereza; HUDECOVÁ Lucia; HUDECOVÁ Lucia
• Rok publikování: 2020
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Česká a slovesnká farmacie
• Fakulta / Pracoviště MU: Farmaceutická fakulta
• www: https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699
• Klíčová slova: SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein
• Popis: The Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.